Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1910220
Max Phase: Preclinical
Molecular Formula: C8H8BrN3S
Molecular Weight: 258.14
Molecule Type: Small molecule
Associated Items:
ID: ALA1910220
Max Phase: Preclinical
Molecular Formula: C8H8BrN3S
Molecular Weight: 258.14
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: NC(=S)N/N=C/c1ccc(Br)cc1
Standard InChI: InChI=1S/C8H8BrN3S/c9-7-3-1-6(2-4-7)5-11-12-8(10)13/h1-5H,(H3,10,12,13)/b11-5+
Standard InChI Key: HMOSVEOPAUPPHT-VZUCSPMQSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 258.14 | Molecular Weight (Monoisotopic): 256.9622 | AlogP: 1.62 | #Rotatable Bonds: 2 |
Polar Surface Area: 50.41 | Molecular Species: NEUTRAL | HBA: 2 | HBD: 2 |
#RO5 Violations: 0 | HBA (Lipinski): 3 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 11.71 | CX Basic pKa: 1.83 | CX LogP: 2.43 | CX LogD: 2.43 |
Aromatic Rings: 1 | Heavy Atoms: 13 | QED Weighted: 0.48 | Np Likeness Score: -2.15 |
1. Aslam MA, Mahmood SU, Shahid M, Saeed A, Iqbal J.. (2011) Synthesis, biological assay in vitro and molecular docking studies of new Schiff base derivatives as potential urease inhibitors., 46 (11): [PMID:21981981] [10.1016/j.ejmech.2011.09.009] |
2. da Silva JB, Navarro DM, da Silva AG, Santos GK, Dutra KA, Moreira DR, Ramos MN, Espíndola JW, de Oliveira AD, Brondani DJ, Leite AC, Hernandes MZ, Pereira VR, da Rocha LF, de Castro MC, de Oliveira BC, Lan Q, Merz KM.. (2015) Thiosemicarbazones as Aedes aegypti larvicidal., 100 [PMID:26087027] [10.1016/j.ejmech.2015.04.061] |
3. Soares MA, Almeida MA, Marins-Goulart C, Chaves OA, Echevarria A, de Oliveira MCC.. (2017) Thiosemicarbazones as inhibitors of tyrosinase enzyme., 27 (15): [PMID:28583798] [10.1016/j.bmcl.2017.05.057] |
4. Ferreira FB, Pereira TM, Souza DLN, Lopes DS, Freitas V, Ávila VMR, Kümmerle AE, Sant'Anna CMR.. (2017) Structure-Based Discovery of Thiosemicarbazone Metalloproteinase Inhibitors for Hemorrhage Treatment in Snakebites., 8 (11): [PMID:29152044] [10.1021/acsmedchemlett.7b00186] |
5. Mathew B, Baek SC, Grace Thomas Parambi D, Pil Lee J, Joy M, Annie Rilda PR, Randev RV, Nithyamol P, Vijayan V, Inasu ST, Mathew GE, Lohidakshan KK, Kumar Krishnan G, Kim H.. (2018) Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors., 9 (11): [PMID:30568755] [10.1039/C8MD00399H] |
6. Hałdys K, Latajka R.. (2019) Thiosemicarbazones with tyrosinase inhibitory activity., 10 (3): [PMID:31015905] [10.1039/C9MD00005D] |
Source(1):